Table 3.
Rates of PVL-negative MSSA, PVL-negative MRSA, PVL-positive MSSA, and PVL-positive MRSA by study sitea
| Study site (total no. of isolates) | No. (%) of isolates in each category |
|||
|---|---|---|---|---|
| PVL negative |
PVL positive |
|||
| MSSA | MRSA | MSSA | MRSA | |
| Australia (n = 90) | 14 (15.6) | 2 (2.2) | 37 (41.1) | 37 (41.1) |
| Germany (n = 50) | 26 (52.0) | 4 (8.0) | 17 (34.0) | 3 (6.0) |
| Saudi Arabia (n = 53) | 21 (39.6) | 8 (15.1) | 11 (20.8) | 13 (24.5) |
| Spain (n = 44) | 11 (25.0) | 0 (0) | 23 (52.3) | 10 (22.7) |
| Sweden (n = 114) | 95 (83.3) | 0 (0) | 19 (16.7) | 0 (0) |
| Trinidad and Tobago (n = 80) | 32 (40.0) | 8 (10.0) | 35 (43.8) | 5 (6.2) |
| Uganda (n = 62) | 39 (62.9) | 4 (6.5) | 19 (30.6) | 0 (0) |
a
Three Australian, six German, eight Saudi, and all English isolates, as well as the reference strains, were excluded from this analysis, because their PVL statuses were known already.